Skip to page content
Back to overview

Jul 23, 2019

Immunotherapy for Chronic Liver Diseases

Life Sciences, Infectious Diseases

  • Novel vaccination strategy against chronic liver diseases through stimulation of IMATEs with TLR9-L
  • IMATEs are an anatomic compartment within the liver tissue consisting of myeloid cells
  • iMATEs overcome regulatory cues that limit immune response during chronic liver infections

Your contact

Dr. Katharina Stoiber

E-Mail:
kstoiber@baypat.de
Phone:
+49 (0) 89 5480177 - 40
Reference Number:
B72272

Challenge

Immunotherapy of chronic hepatitis B is particularly difficult as the hepatic microenvironment is limiting local cytotoxic T lymphocyte (CTL) proliferation after infection. However, CTLs are an important element for overcoming chronic infections of the liver. So far only a prophylactic vaccination against hepatitis B virus is available and a protection post-infection by means of vaccination has not been possible to this point. Accordingly, there is a strong demand for new therapeutic options.

Innovation

A so far unrecognized anatomic compartment within the liver tissue consisting of myeloid cells - called iMATEs (“intrahepatic myeloid-cell aggregates for T cell population expansion”) - can be exploited as a novel vaccination strategy against chronic viral liver infections. iMATEs overcome regulatory cues that limit immune response during chronic liver infections and support local CTL expansion by generation of cocoon-like structures. A dramatic expansion of CTLs in the liver can be achieved by targeted stimulation of iMATEs with TLR9-L as a prophylactic or therapeutic vaccine. The proof-of concept has been shown in vivo in mouse models.

Commercial Opportunities

The present invention provides a convenient and reliable prophylactic as well as therapeutic vaccine strategy. The use of TLR9 agonists induces the formation of iMATEs, which generate a sufficient number of CTLs resulting in the overcoming of chronic viral infections.

Further advantages and opportunities:

  • use as prime - jump strategy for enhancement of CTLs
  • entities of CTLs are increased at least 5 fold in peripheral organs (e.g. liver)
  • use as a prophylactic or therapeutic vaccine against infections with an intracellular pathogen
  • readily available as a kit, containing a prime agent and a multiplying jump agent

Development Status

Proof of concept in vivo.

References

    • Knolle, P.A., Böttcher, J. & Huang, L. The role of hepatic immune regulation in systemic immunity to viral ­ infection. Med Microbiol Immunol. 204, 21 (2015).
    • Hunag, L.R., et al. Intrahepatic myeloid-cell aggregates enable local proliferation of CD8+ T cells and successful immunotherapy against chronic viral liver infection. Nat. Immunol. 14, 574–583 (2013).
    • Protzer, U., Maini, M.K. & Knolle, P.A. Living in the liver: hepatic infections. Nat. Rev. Immunol. 12, 201–213 (2012).

Interested? Get in touch!

Contact a specific team member for individual topics via the Team section or simply use our contact form. You can also click on the button and drop us a line.